title: Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens.
abstract: The addition of antithymocyte globulin (ATG) to a regimen of high-dose cyclophosphamide has been advocated to enhance engraftment after allogeneic bone marrow transplantation (BMT) for severe aplastic anemia (SAA). In a prospective clinical trial, 134 patients were randomly assigned to receive cyclophosphamide alone or in combination with ATG. All patients received T-cell-replete bone marrow from an HLA-matched sibling. With a median follow-up of 6 years, the 5-year probabilities of survival were 74% for the cyclophosphamide alone group and 80% for the cyclophosphamide plus ATG group (P = .44). Graft failure and graft-versus-host disease (GVHD) rates were similar in both groups. With the survival rates achieved, this study is not adequately powered to detect significant differences between the 2 treatment groups. In conclusion, the results of allogeneic BMT for SAA have improved over time related to advances in supportive care. The addition of ATG to the preparative regimen did not significantly improve the outcome.
authors.affiliation: M. D. Anderson Cancer Center, Houston, TX 77030-4095, USA.
authors.forename: Richard E
authors.initials: RE
authors.lastname: Champlin
authors.forename: Waleska S
authors.initials: WS
authors.lastname: Perez
authors.forename: Jakob R
authors.initials: JR
authors.lastname: Passweg
authors.forename: John P
authors.initials: JP
authors.lastname: Klein
authors.forename: Bruce M
authors.initials: BM
authors.lastname: Camitta
authors.forename: Eliane
authors.initials: E
authors.lastname: Gluckman
authors.forename: Christopher N
authors.initials: CN
authors.lastname: Bredeson
authors.forename: Mary
authors.initials: M
authors.lastname: Eapen
authors.forename: Mary M
authors.initials: MM
authors.lastname: Horowitz
mesh_terms: D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection / Q000401:mortality; D006086:Graft vs Host Disease / Q000401:mortality / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007239:Infections / Q000401:mortality; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D014184:Transplantation, Homologous / Q000009:adverse effects
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide